PDVAC: RABIES

Geneva, 22 June, 2017

Bernadette ABELA-RIDDER
WHO Rabies Lead & Team Leader, Neglected Zoonotic Diseases
Department of the Control of Neglected Tropical Diseases
Rabies is a neglected, vaccine-preventable disease
An indicator for impact on inequity

- 100% fatal
- ~60,000 deaths per year
- Weak data and under-reported
- Mostly children
- Vicious cycle of supply and demand
- Vaccine is a key component of the global plan and triggers national programmes

Our Goal: Zero by 30

Rabies per capita death rates per 100,000 persons.
Reaching Zero Rabies deaths by 2030

PREVENT

Awareness, responsible dog ownership, bite prevention and dog vaccination

RESPOND

Bite management and when necessary, post-exposure treatment
Improving and refining

GUIDANCE & STANDARDS

RESEARCH & TECHNOLOGY
Innovation in tools and delivery

MONITOR & EVALUATE
SAGE WG questions

**Pre-Exposure Prophylaxis (PrEP):**
- PreP in particular sub-populations at-risk
- Boosters
- Reduced duration / number PrEP

**Post-exposure Prophylaxis (PEP):**
- Reduced number of doses PEP regimen
- Reduced duration PEP regimen
- PEP for specific risk groups of patients
- Potential of new vaccines for PEP

**Rabies Immunoglobulins (RIG):**
- RIG administration simplified (dose calculation, wound infiltration)
- Safety and efficacy eRIG versus hRIG
- Monoclonal antibodies for RIG
- Prioritizing RIG

**Cost-effectiveness**
- IM vs ID PEP in different settings, shortened schedules, PREP vs PEP
Leaving no-one behind – need for innovation

• improve access
• affordability
• awareness
• programmatic delivery
Relevance for PDVAC

Programme/policy directed R&D

TPP for rabies vaccine – currently none
- Thermostability
- Preservative, adjuvants..
- Fractionating doses but avoiding wastage – WHO standard allows 6 hours before discard
- New technologies: e.g. micro-needle, oral?

New vaccines
- 3 vaccines in clinical testing, 2 vaccines scheduled for clinical testing
- Multiple pre-clinical vaccines

CTC as an option

RIG
- No PQ
- Monoclonal antibodies

New PEP schedules (dose and cost sparing)
- Registry or study efficacy and clinical outcomes
THANK YOU!